Greenleaf Trust raised its stake in Novartis AG (NYSE:NVS – Free Report) by 8.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,601 shares of the company’s stock after purchasing an additional 1,445 shares during the period. Greenleaf Trust’s holdings in Novartis were worth $2,024,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also added to or reduced their stakes in the company. Private Advisor Group LLC lifted its holdings in shares of Novartis by 1.6% during the 3rd quarter. Private Advisor Group LLC now owns 39,056 shares of the company’s stock valued at $4,492,000 after purchasing an additional 608 shares during the last quarter. Leo Wealth LLC increased its position in Novartis by 8.1% during the 3rd quarter. Leo Wealth LLC now owns 13,939 shares of the company’s stock valued at $1,603,000 after buying an additional 1,047 shares in the last quarter. Eastern Bank acquired a new position in Novartis during the 3rd quarter valued at about $19,777,000. Signaturefd LLC raised its stake in Novartis by 4.4% in the third quarter. Signaturefd LLC now owns 40,486 shares of the company’s stock valued at $4,657,000 after buying an additional 1,718 shares during the last quarter. Finally, Foundations Investment Advisors LLC boosted its holdings in Novartis by 10.0% in the third quarter. Foundations Investment Advisors LLC now owns 70,180 shares of the company’s stock worth $8,072,000 after acquiring an additional 6,365 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.
Novartis Price Performance
Novartis stock opened at $114.06 on Thursday. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47. The company has a 50-day moving average price of $116.44 and a 200 day moving average price of $108.39. Novartis AG has a 12-month low of $92.19 and a 12-month high of $120.92. The stock has a market cap of $233.14 billion, a P/E ratio of 14.46, a PEG ratio of 1.70 and a beta of 0.57.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Novartis
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Recommended Stories
- Five stocks we like better than Novartis
- Are Penny Stocks a Good Fit for Your Portfolio?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Why Are These Companies Considered Blue Chips?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Canadian Penny Stocks: Can They Make You Rich?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.